TargED Biopharmaceuticals B.V.
- Address
- Princetonlaan 6
Sponsor Overview
Specializations
Acute Ischemic Stroke
TargED Biopharmaceuticals B.V. is involved in clinical research for acute ischemic stroke, with interest in treatment settings where rapid restoration of blood flow and neurological protection are central concerns.
- Neurovascular thrombosis
- Endovascular thrombectomy
- Acute stroke care
The sponsor’s work in this area reflects a focus on cerebrovascular disease and the management of time-sensitive ischemic injury.
Thrombotic Microangiopathies
The company also funds research in thrombotic microangiopathy, including conditions marked by small-vessel thrombosis, platelet consumption, and organ injury.
- Immune-mediated thrombotic thrombocytopenic purpura
- Microvascular thrombosis
- Platelet disorders
This therapeutic area highlights an interest in complex hematologic and vascular syndromes requiring targeted intervention.
Immune-Mediated Thrombotic Thrombocytopenic Purpura
Research activity includes immune-mediated thrombotic thrombocytopenic purpura, a severe thrombotic disorder associated with acute platelet depletion and systemic microvascular occlusion.
- Acute iTTP episodes
- Thrombocytopenia
- Thrombotic complications
These studies place emphasis on immune-driven coagulation abnormalities and their clinical consequences.
Healthy Volunteer Safety and Pharmacokinetics
The sponsor’s clinical portfolio also includes research in healthy volunteers, supporting early evaluation of safety, tolerability, and pharmacokinetics for investigational biopharmaceutical approaches.
- Safety assessment
- Tolerability
- Pharmacokinetic profiling
This area provides a foundation for development across thrombotic and vascular medicine programs.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| An Adaptive Dose Escalation and Expansion Trial to Evaluate the Safety and Clinical Activity of TGD001 in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura and Other Thrombotic Microangiopathies |  France Germany Italy Spain | Not Yet Recruiting |
| Evaluation of Safety, Tolerability, and Efficacy of TGD001 in Acute Ischemic Stroke Patients with or without Endovascular Thrombectomy | Germany Poland Spain | Recruiting |
| Phase I Randomized, Double-Blind, Placebo-Controlled Study on Safety and Pharmacokinetics of Single-Ascending Doses of TGD001 in Healthy Volunteers | Germany | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 20 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases1 trial359 other sponsors
- 2.Hemic and Lymphatic Diseases1 trial249 other sponsors
- 3.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
20 centres- Address
- Eissendorfer Pferdeweg 52, Heimfeld, 21075 Hamburg
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Chariteplatz 1, 10117 Berlin
- Address
- Via Francesco Sforza 28, 20122 Milan
- Address
- Ul. Ziolowa 45/47, 40-635 Katowice
- Address
- Estrada Clara Campoamor No 341, 36312 Vigo
Want to get in touch with this sponsor?
Send a question and we'll pass it on to TargED Biopharmaceuticals B.V..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.